ALKS — Alkermes plc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1520262 ·
Last close
$37.35
Market Cap
$6.23B
52W High
$39.56
52W Low
$27.00
ADV30
1,895,493
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 392,911,000 | 331,333,000 | -48,280,000 | -66,480,000 | 4,258,076,000 | 351,551,000 | 2,506,545,000 |
| Dec 2025 | 384,547,000 | 338,338,000 | 58,104,000 | 49,341,000 | 2,486,993,000 | 388,570,000 | 667,698,000 |
| Sep 2025 | 394,185,000 | 342,594,000 | 89,082,000 | 82,761,000 | 2,329,512,000 | 616,449,000 | 596,080,000 |
| Jun 2025 | 390,657,000 | 341,197,000 | 92,978,000 | 87,098,000 | 2,252,809,000 | 521,199,000 | 628,225,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$256,200,000
Investing CF
$-1,790,605,000
Financing CF
$1,486,151,000
CapEx
$-44,530,000
Dividends Paid
—
Buybacks
$-27,696,000
EPS Diluted TTM
$0.90
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-801,274,000
Inventory
$336,703,000
Receivables
$407,630,000
ST Investments
$160,311,000
EBIT TTM
$237,204,000
Pretax Income TTM
$204,035,000
Interest Exp TTM
$33,169,000
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,562,300,032
EBITDA
$278,583,008
Free Cash Flow
$140,551,632
Enterprise Value
$7,203,467,776
Total Cash
$511,862,016
Total Debt
$1,581,660,032
Shares Out
166,675,807
Trailing EPS
$0.90
Book Value
$10.52
ROE
9.4%
ROA
4.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,475,899,000 | 253,956,000 | 241,664,000 | 2,486,993,000 | 667,698,000 | — | 520,754,000 |
| Dec 2024 | 1,557,632,000 | 420,636,000 | 367,070,000 | 2,055,567,000 | 590,590,000 | — | 439,124,000 |
| Dec 2023 | 1,663,405,000 | 414,122,000 | 355,757,000 | 2,136,223,000 | 933,537,000 | — | 401,353,000 |
| Dec 2022 | 1,111,795,000 | -6,089,000 | -158,267,000 | 1,963,978,000 | 920,225,000 | — | 21,044,000 |
TTM Snapshot
Revenues TTM
$399,082,000
NetIncome TTM
$-105,686,000
OpCashFlow TTM
$0
Assets (Latest)
$1,797,227,000
Forward EPS
$2.35
Max Pain — expiry 2026-06-18
max pain strike: $35.00 · spot: $37.35 · call oi: 2,156 · put oi: 196
Expected Move to 2026-06-18:
±$3.25
(8.70%) —
implied range
$34.10 –
$40.60
· ATM straddle on $37.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.16B | $89.82 | — |
| CNTA | Centessa Pharmaceuticals plc | $6.16B | $39.78 | — |
| TERN | Terns Pharmaceuticals, Inc. | $6.12B | $52.95 | — |
| TGTX | TG THERAPEUTICS, INC. | $6.08B | $39.73 | — |
| SYRE | Spyre Therapeutics, Inc. | $6.40B | $73.65 | — |
News headlines (Yahoo Finance, 1h cache)
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
2026-05-26 11:00 · Yahoo
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
2026-05-21 11:00 · Yahoo
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear
2026-05-13 18:35 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-05-12 19:58 · Yahoo
Sector Update: Healthcare Stocks Gain in Afternoon Trading
2026-05-12 17:54 · Yahoo
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
2026-05-12 11:00 · Yahoo
Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says
2026-05-06 16:37 · Yahoo
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
2026-05-06 16:06 · Yahoo
Alkermes plc Q1 2026 Earnings Call Summary
2026-05-05 20:46 · Yahoo
Alkermes (ALKS) Q1 2026 Earnings Transcript
2026-05-05 20:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.